The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

Two endocrinologists who live with type 1 diabetes debate this issue at the Advanced Technologies & Treatments for Diabetes ...

The following is a summary of “Evidence for improved glucose metrics and perinatal outcomes with continuous glucose ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM ...